vs
EXACT SCIENCES CORP（EXAS）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Reddit, Inc.的1.2倍（$878.4M vs $725.6M），Reddit, Inc.净利率更高（34.7% vs -9.8%，领先44.5%），Reddit, Inc.同比增速更快（69.7% vs 23.1%），Reddit, Inc.自由现金流更多（$263.6M vs $120.4M），过去两年Reddit, Inc.的营收复合增速更高（72.8% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
EXAS vs RDDT — 直观对比
营收规模更大
EXAS
是对方的1.2倍
$725.6M
营收增速更快
RDDT
高出46.5%
23.1%
净利率更高
RDDT
高出44.5%
-9.8%
自由现金流更多
RDDT
多$143.2M
$120.4M
两年增速更快
RDDT
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $725.6M |
| 净利润 | $-86.0M | $251.6M |
| 毛利率 | 70.1% | 91.9% |
| 营业利润率 | -9.4% | 31.9% |
| 净利率 | -9.8% | 34.7% |
| 营收同比 | 23.1% | 69.7% |
| 净利润同比 | 90.1% | 254.2% |
| 每股收益（稀释后） | $-0.45 | $1.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRDDT
| Q4 25 | $878.4M | $725.6M | ||
| Q3 25 | $850.7M | $584.9M | ||
| Q2 25 | $811.1M | $499.6M | ||
| Q1 25 | $706.8M | $392.4M | ||
| Q4 24 | $713.4M | $427.7M | ||
| Q3 24 | $708.7M | $348.4M | ||
| Q2 24 | $699.3M | $281.2M | ||
| Q1 24 | $637.5M | $243.0M |
净利润EXASRDDT
| Q4 25 | $-86.0M | $251.6M | ||
| Q3 25 | $-19.6M | $162.7M | ||
| Q2 25 | $-1.2M | $89.3M | ||
| Q1 25 | $-101.2M | $26.2M | ||
| Q4 24 | $-864.6M | $71.0M | ||
| Q3 24 | $-38.2M | $29.9M | ||
| Q2 24 | $-15.8M | $-10.1M | ||
| Q1 24 | $-110.2M | $-575.1M |
毛利率EXASRDDT
| Q4 25 | 70.1% | 91.9% | ||
| Q3 25 | 68.6% | 91.0% | ||
| Q2 25 | 69.3% | 90.8% | ||
| Q1 25 | 70.8% | 90.5% | ||
| Q4 24 | 69.0% | 92.6% | ||
| Q3 24 | 69.4% | 90.1% | ||
| Q2 24 | 69.8% | 89.5% | ||
| Q1 24 | 70.0% | 88.6% |
营业利润率EXASRDDT
| Q4 25 | -9.4% | 31.9% | ||
| Q3 25 | -3.0% | 23.7% | ||
| Q2 25 | -0.3% | 13.6% | ||
| Q1 25 | -13.6% | 1.0% | ||
| Q4 24 | -122.8% | 12.4% | ||
| Q3 24 | -5.6% | 2.0% | ||
| Q2 24 | -3.8% | -11.0% | ||
| Q1 24 | -16.7% | -242.5% |
净利率EXASRDDT
| Q4 25 | -9.8% | 34.7% | ||
| Q3 25 | -2.3% | 27.8% | ||
| Q2 25 | -0.1% | 17.9% | ||
| Q1 25 | -14.3% | 6.7% | ||
| Q4 24 | -121.2% | 16.6% | ||
| Q3 24 | -5.4% | 8.6% | ||
| Q2 24 | -2.3% | -3.6% | ||
| Q1 24 | -17.3% | -236.7% |
每股收益（稀释后）EXASRDDT
| Q4 25 | $-0.45 | $1.24 | ||
| Q3 25 | $-0.10 | $0.80 | ||
| Q2 25 | $-0.01 | $0.45 | ||
| Q1 25 | $-0.54 | $0.13 | ||
| Q4 24 | $-4.69 | $4.76 | ||
| Q3 24 | $-0.21 | $0.16 | ||
| Q2 24 | $-0.09 | $-0.06 | ||
| Q1 24 | $-0.60 | $-8.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $953.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.9B |
| 总资产 | $5.9B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASRDDT
| Q4 25 | $964.7M | $953.6M | ||
| Q3 25 | $1.0B | $911.7M | ||
| Q2 25 | $858.4M | $734.1M | ||
| Q1 25 | $786.2M | $635.7M | ||
| Q4 24 | $1.0B | $562.1M | ||
| Q3 24 | $1.0B | $515.9M | ||
| Q2 24 | $946.8M | $468.0M | ||
| Q1 24 | $652.1M | $968.5M |
股东权益EXASRDDT
| Q4 25 | $2.4B | $2.9B | ||
| Q3 25 | $2.5B | $2.6B | ||
| Q2 25 | $2.5B | $2.4B | ||
| Q1 25 | $2.4B | $2.2B | ||
| Q4 24 | $2.4B | $2.1B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $1.9B | ||
| Q1 24 | $3.1B | $1.8B |
总资产EXASRDDT
| Q4 25 | $5.9B | $3.2B | ||
| Q3 25 | $5.9B | $2.9B | ||
| Q2 25 | $5.8B | $2.6B | ||
| Q1 25 | $5.7B | $2.4B | ||
| Q4 24 | $5.9B | $2.3B | ||
| Q3 24 | $6.7B | $2.2B | ||
| Q2 24 | $6.7B | $2.1B | ||
| Q1 24 | $6.4B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $266.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $263.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 36.3% |
| 资本支出强度资本支出/营收 | 3.6% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.06× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $684.2M |
8季度趋势，按日历期对齐
经营现金流EXASRDDT
| Q4 25 | $151.7M | $266.8M | ||
| Q3 25 | $219.9M | $185.2M | ||
| Q2 25 | $89.0M | $111.3M | ||
| Q1 25 | $30.8M | $127.6M | ||
| Q4 24 | $47.1M | $90.0M | ||
| Q3 24 | $138.7M | $71.6M | ||
| Q2 24 | $107.1M | $28.4M | ||
| Q1 24 | $-82.3M | $32.1M |
自由现金流EXASRDDT
| Q4 25 | $120.4M | $263.6M | ||
| Q3 25 | $190.0M | $183.1M | ||
| Q2 25 | $46.7M | $110.8M | ||
| Q1 25 | $-365.0K | $126.6M | ||
| Q4 24 | $10.7M | $89.2M | ||
| Q3 24 | $112.6M | $70.3M | ||
| Q2 24 | $71.2M | $27.2M | ||
| Q1 24 | $-120.0M | $29.2M |
自由现金流率EXASRDDT
| Q4 25 | 13.7% | 36.3% | ||
| Q3 25 | 22.3% | 31.3% | ||
| Q2 25 | 5.8% | 22.2% | ||
| Q1 25 | -0.1% | 32.3% | ||
| Q4 24 | 1.5% | 20.8% | ||
| Q3 24 | 15.9% | 20.2% | ||
| Q2 24 | 10.2% | 9.7% | ||
| Q1 24 | -18.8% | 12.0% |
资本支出强度EXASRDDT
| Q4 25 | 3.6% | 0.4% | ||
| Q3 25 | 3.5% | 0.4% | ||
| Q2 25 | 5.2% | 0.1% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 3.7% | 0.4% | ||
| Q2 24 | 5.1% | 0.4% | ||
| Q1 24 | 5.9% | 1.2% |
现金转化率EXASRDDT
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 4.88× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 2.40× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RDDT
| Advertising | $689.7M | 95% |
| Other Revenue | $35.9M | 5% |
